These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 33222473)

  • 1. Overall clinical and economic impact of non-alcoholic fatty liver disease.
    Sicras-Mainar A; Aller R; Crespo J; Calleja JL; Turnes J; Romero Gómez M; Augustín S
    Rev Esp Enferm Dig; 2021 Jun; 113(6):396-403. PubMed ID: 33222473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain.
    Sicras-Mainar A; Navarro-Artieda R; Sáez-Zafra M
    Gastroenterol Hepatol; 2018 Apr; 41(4):234-244. PubMed ID: 29287992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue.
    Mak LY; Lee CH; Cheung KS; Wong DK; Liu F; Hui RW; Fung J; Xu A; Lam KS; Yuen MF; Seto WK
    Liver Int; 2019 Jul; 39(7):1217-1225. PubMed ID: 30912255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
    Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis.
    Tapper EB; Bonafede M; Fishman J; Dodge S; Miller K; Zeng N; Lewandowski D; Bogdanov A
    J Med Econ; 2023; 26(1):348-356. PubMed ID: 36866575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
    Wong RJ; Liu B; Bhuket T
    Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
    McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
    Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
    Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
    AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
    [No Abstract]   [Full Text] [Related]  

  • 14. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.
    Singh A; Le P; Lopez R; Alkhouri N
    Hepatol Int; 2018 Jan; 12(1):37-43. PubMed ID: 29318450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
    Younossi ZM; Stepanova M; Anstee QM; Lawitz EJ; Wai-Sun Wong V; Romero-Gomez M; Kersey K; Li G; Subramanian GM; Myers RP; Djedjos CS; Okanoue T; Trauner M; Goodman Z; Harrison SA
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2552-2560.e10. PubMed ID: 30779990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study.
    Pitisuttithum P; Chan WK; Piyachaturawat P; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Fan JG; Song MJ; Yoon SK; Dan YY; Lesmana L; Ho KY; Goh KL; Wong VWS; Treeprasertsuk S
    BMC Gastroenterol; 2020 Apr; 20(1):88. PubMed ID: 32252638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
    Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
    World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.